NCT02370095 - Treprostinil Sodium Inhalation for Patients At High Risk for ARDS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

October 11, 2017

Study Completion Date

November 7, 2017

Conditions

Respiratory Distress Syndrome, Adult

Interventions

DRUG

Treprostinil Inhalation Solution

Treprostinil inhalation solution administered as blinded marketed product

DRUG

Placebo

Supplied by the manufacturer and similar to the active drug but containing no Treprostinil

Trial Locations (1)

University of North Carolina Hospitals, Chapel Hill